Bacillus Coagulans Benefits: What the Clinical Evidence Actually Shows
A research-backed look at why this spore-forming probiotic outperforms conventional strains
Of the hundreds of probiotic strains studied in human clinical trials, Bacillus coagulans occupies an unusual position. It behaves like a lactic acid bacterium—producing the same beneficial metabolites as the Lactobacillus strains in your yogurt—while also forming dormant spores that survive conditions lethal to nearly every other probiotic on the market. That combination of properties has made B. coagulans one of the most clinically investigated probiotic species of the past two decades, with randomized controlled trials spanning irritable bowel syndrome, digestive gas, immune function, and even exercise recovery.
This article examines the peer-reviewed evidence for Bacillus coagulans benefits, explains what makes it mechanistically distinct from conventional probiotic strains, and addresses the practical questions most supplement shoppers don't think to ask—including which strains have the strongest clinical backing, what the research says about dosing, and why the capsule and filler choices surrounding a B. coagulans supplement matter just as much as the organism itself.
Key Takeaways
- Bacillus coagulans is a spore-forming, lactic acid-producing probiotic that survives gastric acid, bile salts, and heat that destroy most conventional probiotic strains.[1]
- Multiple randomized, double-blind, placebo-controlled trials demonstrate significant reductions in IBS symptoms including bloating, abdominal pain, and abnormal stool frequency.[2][3]
- Clinical data support a gut-brain connection: B. coagulans MTCC 5856 significantly improved depression scores in IBS patients, suggesting meaningful influence over the gut-brain axis.[4]
- Co-administration with protein improves amino acid absorption and has been shown to reduce exercise-induced muscle damage and accelerate recovery.[5][6]
- Safety is well-established: Comprehensive toxicological assessments show no mutagenic, clastogenic, or genotoxic effects, and the FDA has granted multiple B. coagulans strains GRAS (Generally Recognized as Safe) status.[1]
- MicroBiome Restore includes Bacillus coagulans as part of a 26-strain, 15 Billion CFU formula, alongside five additional Bacillus species and prebiotics that feed the beneficial bacteria it delivers.
What Is Bacillus Coagulans?
Bacillus coagulans is a Gram-positive, facultatively anaerobic bacterium first isolated in 1915 from spoiled canned milk by bacteriologist B.W. Hammer—a fitting origin story for a microorganism whose core survival strategy involves enduring environments hostile to nearly everything else. For much of the 20th century it was classified as Lactobacillus sporogenes, a name that reveals its dual identity: it produces L(+) lactic acid like the Lactobacillus genus, yet unlike any true Lactobacillus, it forms protective endospores.[1]
Reclassified as Bacillus coagulans in Bergey's Manual of Systematic Bacteriology (1974), the species has since gained substantial commercial and scientific traction. Dozens of proprietary strains now exist under trade names including BC30 (GBI-30, 6086), LactoSpore® (MTCC 5856), Unique IS-2, and SNZ 1969—and it's worth understanding that strain designations matter clinically. Studies on one strain don't automatically transfer to another; efficacy data are strain-specific.
How Bacillus Coagulans Fits Into a Multi-Strain Formula
Most probiotic research focuses on Lactobacillus and Bifidobacterium species—the workhorse genera of conventional supplements. Bacillus coagulans belongs to a distinct functional category: spore-forming probiotics, sometimes called soil-based organisms. While Lactobacillus and Bifidobacterium strains are highly studied for colonization effects, Bacillus species offer complementary benefits rooted in their stability and their production of antimicrobial compounds, digestive enzymes, and short-chain fatty acids. A well-designed multi-strain formula incorporates both categories—not one at the expense of the other.
In terms of nomenclature: in 2020, a genomics-based reclassification proposed renaming the species Weizmannia coagulans, and a subsequent proposal has called it Heyndrickxia coagulans. Regulatory agencies and the vast majority of peer-reviewed literature still use Bacillus coagulans, and this article follows that convention.
Why Bacillus Coagulans Survives Where Other Probiotics Fail
The fundamental challenge facing any probiotic is delivery: the organism must survive the acidic environment of the stomach (pH 1.5–3.5), endure exposure to bile salts in the small intestine, and arrive at the colon viable and in sufficient numbers to exert its effects. For most conventional probiotic strains, these are meaningful hurdles. Lactobacillus rhamnosus GG—among the most studied strains in the world—has demonstrated significant viability loss under simulated gastric and intestinal conditions, while B. coagulans spores show no significant decrease in viable counts under identical conditions.[7]
The Spore Mechanism
When conditions become unfavorable—whether due to heat, desiccation, or gastric acid—B. coagulans encapsulates itself in a protective protein-coated endospore. This dormant state is metabolically inert and nearly impervious to environmental assault. Once the spore reaches the more hospitable environment of the small intestine, it germinates, the vegetative cell emerges, and probiotic activity begins.[8]
This germination-in-the-gut behavior has two practical implications. First, the probiotic delivers viable organisms where they're needed without requiring refrigeration, enteric coatings, or expensive encapsulation technologies. Second, it means B. coagulans can be incorporated into applications—including functional foods subjected to heat processing—where Lactobacillus and Bifidobacterium strains would not survive. Multiple strains have received GRAS status from the FDA specifically because comprehensive toxicological assessments have found no mutagenic, clastogenic, or genotoxic activity and established a no-observed-adverse-effect level (NOAEL) exceeding 1,000 mg/kg per day in animal models.[1]
Transient Colonization: What It Means for Dosing
Unlike autochthonous bacteria that permanently colonize the gut, B. coagulans is allochthonous—it colonizes transiently. Research suggests it is cleared from the gastrointestinal tract within four to five days when supplementation stops.[1] This is not a weakness; it's why the organism has such a strong safety profile. It does its work, modulates the gut environment, and exits without persistent residency. Consistent daily supplementation maintains the beneficial effects demonstrated in clinical trials.
Clinical Evidence for Digestive Health
Bacillus coagulans has accumulated some of the most robust clinical evidence of any probiotic strain for gastrointestinal applications—particularly irritable bowel syndrome (IBS) and functional digestive complaints. The trial designs are generally rigorous: randomized, double-blind, placebo-controlled, and multi-centered.
Irritable Bowel Syndrome (IBS)
A double-blind, randomized, placebo-controlled pilot study published in Nutrition Journal enrolled 36 patients with newly diagnosed diarrhea-predominant IBS. Participants receiving B. coagulans MTCC 5856 at 2 × 10⁹ CFU/day for 90 days experienced statistically significant improvements compared to placebo across every primary endpoint: bloating (p = 0.0037), diarrhea (p = 0.0026), abdominal pain (p = 0.0001), and stool frequency (p = 0.0031). Physician-assessed disease severity and IBS quality-of-life scores improved significantly in the probiotic group as well.[2]
A separate 12-week multicenter RCT involving 100 IBS patients found that B. coagulans BCP92 produced statistically significant improvements in IBS severity scores (p < 0.001), gastrointestinal symptom frequency (p < 0.001), and stool consistency (p < 0.001) versus placebo. Notably, the probiotic group also showed meaningful reductions in mental stress and anxiety ratings—an outcome that points toward systemic effects well beyond the gut lumen.[9]
Gas and Bloating
For individuals who don't meet formal IBS diagnostic criteria but experience chronic functional gas and bloating, a multicenter RCT published in 2023 provides relevant evidence. Seventy adults with GSRS indigestion scores ≥ 5 were randomized to 2 billion spores/day of B. coagulans MTCC 5856 or placebo for four weeks. The probiotic group's indigestion scores fell by 65.5%, compared to 11.5% in the control group. Other GI symptom subscales—reflux, diarrhea, constipation, and abdominal pain—improved by 84.1% in the probiotic group versus 33.65% in the placebo group.[3]
Bacillus Coagulans in a Complete Digestive Formula
The digestive benefits of B. coagulans are amplified when paired with complementary probiotic strains and prebiotic substrates. MicroBiome Restore includes Bacillus coagulans alongside 25 additional clinically relevant strains—including Lactobacillus rhamnosus, Lactobacillus plantarum, and Bifidobacterium longum—and nine organic prebiotics (Jerusalem artichoke, maitake mushroom, acacia, fig fruit, bladderwrack, Norwegian kelp, and oarweed) that fuel the bacteria being delivered. At 15 Billion CFU per serving, the formula is designed for comprehensive microbiome support, not just single-organism supplementation. See our complete formulation guide for the full breakdown.
For those managing conditions like SIBO alongside IBS symptoms, evidence-based probiotic selection for SIBO requires additional strain-level consideration—not all probiotic species are appropriate for all presentations of small intestinal bacterial overgrowth, and the spore-forming character of B. coagulans may offer advantages in that context.
Immune Modulation and the Gut-Brain Axis
Immunomodulatory Effects
The immune effects of B. coagulans have been characterized in multiple in vitro and in vivo studies. A double-blind, placebo-controlled crossover study in adults aged 65–80 years found that 28 days of B. coagulans GBI-30, 6086 supplementation significantly increased Faecalibacterium prausnitzii—a keystone anti-inflammatory species—in fecal samples, alongside elevated anti-inflammatory cytokine responses in peripheral blood mononuclear cells (PBMCs).[10]
A separate randomized, double-blind, placebo-controlled trial in 80 healthy school-age children found that daily supplementation with B. coagulans GBI-30, 6086 for three months significantly reduced the incidence and duration of upper respiratory tract infection symptoms including nasal congestion, hoarseness, and fatigue, while also reducing flatulence. These effects were associated with measurable modulation of immune-related serum proteins including TNFα, IL-6, and G-CSF—a growth factor involved in post-injury immune repair.[11]
In vitro research using human PBMC cultures has demonstrated that B. coagulans cell walls activate CD3+ T lymphocytes, NKT cells, and NK cells while simultaneously upregulating anti-inflammatory cytokine production—a profile consistent with trained immunity rather than nonspecific immune stimulation.[12]
Gut-Brain Axis: Emerging Clinical Evidence
The gut-brain axis is increasingly recognized as a bidirectional communication highway between gut microbiota and central nervous system function. The most striking clinical evidence for B. coagulans' role in this pathway comes from a 90-day, multicenter, randomized, double-blind, placebo-controlled trial in 40 patients diagnosed with major depressive disorder (MDD) co-occurring with IBS. Patients receiving 2 billion spores/day of B. coagulans MTCC 5856 showed statistically significant improvements (p = 0.01) across all primary efficacy measures: the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-Åsberg Depression Rating Scale (MADRS), and the Center for Epidemiological Studies Depression Scale (CES-D), alongside meaningful gains in IBS quality-of-life scores.[4]
The mechanisms underlying this connection are not fully elucidated, but are thought to involve microbial modulation of neurotransmitter precursors, short-chain fatty acid production, and vagal nerve signaling. What the trial demonstrates clearly is that restoring microbial balance—specifically using B. coagulans—can produce measurable improvements in mental health outcomes in a clinical population, not just gut symptoms.
Protein Absorption and Exercise Recovery
An underappreciated dimension of B. coagulans research involves its effects on nutrient metabolism—particularly protein digestion and utilization. This has obvious implications for athletes, active individuals, and aging populations where muscle protein synthesis is a priority.
Enhanced Amino Acid Absorption
Once B. coagulans germinates in the small intestine, the vegetative cells produce alkaline proteases and other digestive enzymes that augment endogenous digestive capacity. A review published in Probiotics and Antimicrobial Proteins concluded that B. coagulans GBI-30, 6086 can withstand gastric acid to reach the intestine, where co-administration with protein significantly increases protein absorption and maximizes the health benefits associated with protein supplementation—with particular relevance for lower-leucine plant protein sources.[5]
A subsequent human clinical trial confirmed the mechanistic picture: 30 participants ingesting a 25g dose of milk protein concentrate with BC30 showed significantly higher post-prandial blood amino acid concentrations compared to protein alone, demonstrating measurable enhancement of protein digestion and amino acid bioavailability in a real-world supplementation context.[6]
Exercise-Induced Muscle Damage and Recovery
A peer-reviewed exercise science trial published in PeerJ assigned recreationally trained males to either casein protein alone or casein plus 1 billion CFU of B. coagulans GBI-30, 6086 using a crossover design. The probiotic group showed significantly accelerated recovery at 24 and 72 hours post-exercise, reduced muscle soreness at 72 hours, and a notably attenuated rise in creatine kinase (CK)—a biomarker of muscle damage—compared to protein alone (+137.7% vs. +266.8%). Strenuous exercise significantly reduced athletic performance in the protein-only group, while the probiotic group maintained performance.[13]
Why This Matters Beyond Athletes
Sarcopenia—age-related muscle loss—is driven in part by impaired protein digestion and reduced anabolic response to dietary amino acids. The evidence that B. coagulans improves amino acid bioavailability isn't just relevant for gym-goers; it suggests meaningful value for older adults seeking to maintain muscle mass and functional strength. This complements what we already know about the broader relationship between gut microbiome diversity and healthy aging.
Choosing a Quality Bacillus Coagulans Supplement
Not all Bacillus coagulans supplements deliver what the clinical literature demonstrates. Several variables determine whether a product will produce the outcomes reported in RCTs—and most of them appear in the inactive ingredients, not the featured probiotic.
Strain Identity and CFU Count
Clinical trials have used doses ranging from 2 × 10⁸ to 6 × 10⁹ CFU/day across different B. coagulans strains. Strain designation matters: MTCC 5856, GBI-30 (6086), LBSC, and BCP92 are among the most clinically characterized. If a label simply says "Bacillus coagulans" without a strain designation, there's no way to match the product to the evidence base. Look for strain-level specificity.
The Filler Problem
Here's something most consumers don't consider: several of the most common fillers in probiotic supplements—including microcrystalline cellulose, magnesium stearate, and silicon dioxide—are added purely for manufacturing convenience and contribute nothing to your health. In the case of microcrystalline cellulose, emerging research raises specific questions about its effects on the gut environment that are relevant to anyone supplementing probiotics. Our guide to flow agents and fillers in probiotic supplements covers the full landscape if you want to evaluate any product label critically.
| What to Look For | Why It Matters |
|---|---|
| Named strain designation (e.g., MTCC 5856, GBI-30) | Allows you to match the product to clinical trial evidence |
| CFU count at expiry, not at manufacture | Potency claims should hold through the best-by date |
| No microcrystalline cellulose or magnesium stearate | Common fillers that add no benefit and may interfere with gut health goals |
| Prebiotic substrate included | Probiotics need fuel; fermentable fibers support colonization and metabolite production |
| Multi-strain formula | Diversity mirrors a healthy gut ecosystem; single-strain products are limiting |
| Spore stability without refrigeration | B. coagulans spores are inherently shelf-stable—no cold chain required |
Capsule Material
Capsule composition matters more than most consumers realize. Gelatin capsules are the cheapest option and are animal-derived. HPMC (hypromellose) capsules are synthetic and carry their own trade-offs. Pullulan capsules—derived from fermented tapioca—provide delayed release to the large intestine while contributing fermentable polysaccharide material that the gut microbiome can use directly. For a probiotic supplement, that's an active ingredient hiding in what most companies treat as packaging.
If you're evaluating a multi-strain probiotic without MCC, the question isn't just whether the formula contains good organisms—it's whether the rest of the product is designed with the same care as the strain selection. At BioPhysics Essentials, that philosophy extends from the spore count to the capsule shell.
MicroBiome Restore: Bacillus Coagulans and 25 More Evidence-Based Strains
MicroBiome Restore delivers 15 Billion CFU across 26 strains—including Bacillus coagulans and five additional Bacillus species—with nine organic prebiotic substrates and zero synthetic fillers. No microcrystalline cellulose. No magnesium stearate. Pullulan capsules for delayed release. Every ingredient earns its place.
Frequently Asked Questions
What are the main benefits of Bacillus coagulans?
The most rigorously documented benefits from peer-reviewed clinical trials include: reduction of IBS symptoms (bloating, abdominal pain, diarrhea, and stool irregularity), improvement of functional gas and digestive discomfort, immune modulation including enhanced anti-inflammatory cytokine production and NK cell activity, measurable improvements in mood and depression scores in IBS patients, and improved protein absorption and exercise recovery when taken with dietary protein.
Who should not take Bacillus coagulans?
Bacillus coagulans has an excellent safety profile and GRAS status with the FDA. Clinical trials have included adults and children without significant adverse events. However, individuals who are severely immunocompromised, those recovering from major surgery, or people with central venous catheters are typically advised to consult a healthcare provider before taking any probiotic, including B. coagulans. As with all supplements, pregnant or breastfeeding individuals should seek professional guidance before use.
Can Bacillus coagulans help with acne?
There is a plausible mechanistic pathway: B. coagulans modulates gut-associated immune responses and reduces systemic inflammatory markers. Given the well-documented gut-skin axis and the role of inflammation in acne pathogenesis, probiotic supplementation is a reasonable supportive strategy. However, direct clinical trials specifically for acne using B. coagulans are limited. The broader evidence on probiotics and skin conditions suggests that reducing gut-derived inflammatory load can benefit skin health.
Is Bacillus coagulans good for IBD?
Inflammatory bowel disease (IBD)—including Crohn's disease and ulcerative colitis—is distinct from IBS and involves structural intestinal inflammation rather than a functional disorder. Preclinical research and limited clinical data suggest B. coagulans may have anti-inflammatory properties relevant to IBD, and animal studies have shown protection against induced colitis. However, IBD management requires physician supervision, and probiotic use in active IBD should always be discussed with a gastroenterologist. The evidence base for B. coagulans in IBD is substantially less mature than its evidence for IBS.
What is the typical dosage for Bacillus coagulans?
Clinical trials have used doses ranging from approximately 200 million to 6 billion CFU per day depending on the strain and indication, with the majority of IBS trials using 2 × 10⁹ (2 billion) CFU/day. Most supplements deliver between 1–5 billion CFU per serving. When B. coagulans is part of a comprehensive multi-strain formula, the total CFU of the formula will typically exceed the dose used in single-strain trials—this is appropriate, as the organisms work synergistically and additional strains cover complementary mechanisms.
Does Bacillus coagulans need to be refrigerated?
No. This is one of its defining advantages over conventional probiotic strains. The spore form is inherently shelf-stable and does not require refrigeration to maintain viability. B. coagulans MTCC 5856 has been demonstrated to remain stable during processing and storage of functional foods, including baked goods. Look for products that state CFU potency at expiry rather than at the time of manufacture to ensure the count on the label holds throughout its shelf life.
Bottom Line
Bacillus coagulans sits in a genuinely unique position in the probiotic landscape. It is not a trendy new ingredient—it has been studied in human clinical trials for decades, has received GRAS status from the FDA, and has an evidence base that spans digestive disease, immune function, mental health, and athletic performance. Its spore-forming nature solves delivery problems that have plagued conventional probiotics since the beginning of the supplement category.
What matters most when selecting a supplement is context: B. coagulans works best as part of a formula that recognizes the complexity of the human microbiome, pairs it with complementary strains covering different niches, and provides prebiotic substrates to sustain the bacterial communities being introduced. When you also remove the unnecessary fillers that most manufacturers include by default, you get a product designed around what actually supports your gut—not what makes production easier.
Review the hidden fillers in most probiotic supplements before your next purchase, and consider whether the product you're currently using was formulated with the same level of scrutiny applied to its clinical evidence.
Ready to Experience the Difference?
MicroBiome Restore combines Bacillus coagulans with 25 complementary probiotic strains, nine organic prebiotics, and 80+ trace minerals—all in filler-free pullulan capsules designed for delayed release to the large intestine.
References
- Endres, J. R., Clewell, A., Jones, K. A., Thapar, T., Shim, J., & Bausman, A. (2009). Safety assessment of a proprietary preparation of a novel probiotic, Bacillus coagulans, as a food ingredient. Food and Chemical Toxicology, 47(6), 1231–1238. https://doi.org/10.1016/j.fct.2009.02.018 | PMC Full Text
- Majeed, M., Nagabhushanam, K., Natarajan, S., Sivakumar, A., Ali, F., Pande, A., & Majeed, S. (2016). Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutrition Journal, 15, 21. https://doi.org/10.1186/s12937-016-0140-6 | PMC Full Text
- Majeed, M., Nagabhushanam, K., Paulose, S., Arumugam, S., & Mundkur, L. (2023). The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: a randomized, double-blind, placebo-controlled study. Medicine, 102(10), e33121. https://doi.org/10.1097/MD.0000000000033121 | PMC Full Text
- Majeed, M., Nagabhushanam, K., Arumugam, S., Majeed, S., & Ali, F. (2018). Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food & Nutrition Research, 62. https://doi.org/10.29219/fnr.v62.1218 | PMC Full Text
- Jäger, R., Purpura, M., Farmer, S., Cash, H. A., & Keller, D. (2018). Probiotic Bacillus coagulans GBI-30, 6086 improves protein absorption and utilization. Probiotics and Antimicrobial Proteins, 10(4), 611–615. https://doi.org/10.1007/s12602-017-9354-y | PMC Full Text
- Jäger, R., Shields, K. A., Lowery, R. P., De Souza, E. O., Partl, J. M., Hollmer, C., Purpura, M., & Wilson, J. M. (2020). Bacillus coagulans GBI-30, 6086 improves amino acid absorption from milk protein. Nutrition & Metabolism, 17, 93. https://doi.org/10.1186/s12986-020-00534-z | PMC Full Text
- Shinde, T., Vemuri, R., Shastri, M. D., Perera, A. P., Tristram, S., Stanley, R., & Eri, R. (2019). Probiotic Bacillus coagulans MTCC 5856 spores exhibit excellent in-vitro functional efficacy in simulated gastric survival, mucosal adhesion and immunomodulation. Journal of Functional Foods, 52, 100–108. https://doi.org/10.1016/j.jff.2018.10.031
- Cao, J., Yu, Z., Liu, W., Zhao, J., Zhang, H., Zhai, Q., & Chen, W. (2020). Probiotic characteristics of Bacillus coagulans and associated implications for human health and diseases. Journal of Functional Foods, 64, 103643. https://doi.org/10.1016/j.jff.2019.103643
- Divekar, H. M., Bhardwaj, R., Vaid, N., Agarwal, A., Jain, S., Sharma, S., & Shukla, V. (2025). Role of Bacillus coagulans (Heyndrickxia coagulans) BCP92 in managing irritable bowel syndrome: a randomized, double-blind, multicenter, placebo-controlled clinical trial. Medicine, 103(32), e39291. https://doi.org/10.1097/MD.0000000000039291 | PMC Full Text
- Nyangale, E. P., Farmer, S., Cash, H. A., Keller, D., Chernoff, D., & Gibson, G. R. (2015). Bacillus coagulans GBI-30, 6086 modulates Faecalibacterium prausnitzii in older men and women. Journal of Nutrition, 145(7), 1446–1452. https://doi.org/10.3945/jn.114.199802
- Sánchez-Ruiz, J. A., Vásquez-Garibay, E. M., Larrosa-Haro, A., Salazar-Lindo, E., Polanco-Allué, I., Ontiveros-Nevares, P. G., ... & Gutiérrez-Castrellón, P. (2019). Bacillus coagulans GBI-30, 6086 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins. Beneficial Microbes, 10(7), 729–748. https://doi.org/10.3920/BM2018.0197
- Jensen, G. S., Hart, A. N., & Zaske, L. A. (2020). Inactivated probiotic Bacillus coagulans GBI-30 induces complex immune activating, anti-inflammatory, and regenerative markers in vitro. Journal of Inflammation Research, 13, 353–367. https://doi.org/10.2147/JIR.S248265 | PMC Full Text
- Jäger, R., Shields, K. A., Lowery, R. P., De Souza, E. O., Partl, J. M., Hollmer, C., Purpura, M., & Wilson, J. M. (2016). Probiotic Bacillus coagulans GBI-30, 6086 reduces exercise-induced muscle damage and increases recovery. PeerJ, 4, e2276. https://doi.org/10.7717/peerj.2276 | PMC Full Text
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!